Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT05515055 |
| Other study ID # |
ED22/147142 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
April 7, 2022 |
| Est. completion date |
December 31, 2024 |
Study information
| Verified date |
July 2023 |
| Source |
The Leeds Teaching Hospitals NHS Trust |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Addison's disease is a condition that leads to a reduction in production of steroid hormones
from the adrenal glands. These hormones, particularly cortisol have many important roles in
the body, one of which is increasing blood sugar. These steroids will be replaced with
tablets but fails to mimic the normal increase in natural cortisol levels which increase from
around 2am in the early morning. Furthermore, steroid tablets have been associated with
stopping patients from going to sleep.
Patients with Addison's disease on treatment still complain of excessive fatigue and have an
increased risk of death from blood vessel diseases. Some case reports have shown some
patients with Addison's disease to have low blood sugars overnight.
To investigate the possible causes of fatigue in Addison's disease by examining sugar levels
and sleep patterns of our patients. Blood clotting will also be looked at as a potential
mechanism for the unexplained increase in blood vessel diseases. To examine sugar levels a
small probe will be attached to the upper arm which the patients will wear for 14 days to
measure blood glucose very regularly and is painless. Additionally the patients will wear a
watch that monitors sleep, movement, and light. A single blood sample will be taken to
measure vascular risk markers and how the blood clots.
After wearing the monitors the subjects will complete questionnaires assessing quality of
life. Healthy individuals will be recruited to undergo the same monitoring to act as a
control group.
The data data obtained between Addison's disease and healthy subjects will be compared.
The scores from the questionnaires will be compared to the glucose and sleep readings to
ascertain if there is a link between low blood sugars or sleep disturbance and their quality
of life to determine if any physical abnormalities translate in to the poor quality of life.
Description:
Patients with primary adrenal insufficiency (PAI) have impaired subjective health status (1,
2) and excess mortality (3, 4). Cardiovascular disease is the greatest contributor towards
the excess mortality (3). How current glucocorticoid replacement translates into these
adverse sequelea is not understood. Excess and inadequate glucocorticoid replacement likely
both contribute. Endogenous cortisol levels rapidly increase from 2am, peaking before waking,
and thereafter fall through the day to a nadir around midnight. Hydrocortisone is the
preferred glucocorticoid used for replacement therapy in PAI. Current glucocorticoid
replacement regimens try to mimic the normal diurnal cortisol rhythm (5). The most commonly
used regimens involve use of hydrocortisone (bio-identical to cortisol) administered three
times per day (6). As cortisol levels are highest in the morning and fall through the day, a
larger dose of hydrocortisone is given on waking with small doses thereafter. It is important
in the timing of these doses that there is overlap to avoid periods of cortisol
insufficiency. Although regimens aim to replicate the daytime cortisol profile, they cannot
currently provide replacement in the early morning hours (2am-7am). This leads to a period of
glucocorticoid insufficiency during sleep. Studies using continuous subcutaneous infusion
(CSII) of hydrocortisone deliver hydrocortisone in a manner that mimics the normal diurnal
rhythm of cortisol, including the period between 2am and waking. Hydrocortisone delivered by
CSII has been associated with improvements in well-being in patients with PAI (7), though
have not been used in an adequate number of patients for long enough duration to assess the
impact on the excess mortality.
Insulin sensitivity is greatest between 2am-4am consequent on the diurnal rhythm of insulin
counter-regulatory hormones. Consequently type I diabetic patients are at greatest risk of
hypoglycaemia at this time. Glucocorticoid insufficiency increases glucose oxidation and
decreases glucose production translating to increased insulin sensitivity. PAI is associated
with hypoglycaemic events, though generally in children rather than adults. Using continuous
glucose monitoring (CGM) a single case report (8) and a small series identified two patients
with nocturnal hypoglycaemia (9). The series did not contain a control group and therefore
was unable to determine if nocturnal glucose levels were lower in the patients compared with
the normal population.
Furthermore, glucocorticoids have been associated with disruption of sleep, particularly
difficulties getting to sleep (10). Therefore taking of replacement hydrocortisone after 6pm
in the evening is avoided so that the majority of the hydrocortisone will have been
metabolised before the patients retires to sleep. There are however marked differences in the
timing of doses of hydrocortisone with patients often taking their doses around other life
commitments, or when they are most likely to remember (i.e. first thing in the morning and
last thing at night). A significant proportion of patients therefore take their last dose of
steroids in the late evening or immediately prior to trying to sleep (6). This can lead
hydrocortisone being taken later than prescribed and potentially impacting on sleep. However,
as the dose of replacement hydrocortisone is low when given in the evening it is not known if
sleep is adversely affected in contrast to that observed with higher therapeutic doses of
glucocorticoids?
Finally, much of the excess mortality of patients with primary adrenal insufficiency is
reported to relate to vascular disease (3). Vascular risk factors are variably reported to be
increased in PAI (11). However, the mechanism by which the excess vascular disease occurs
remains incompletely understood.
